文献速递前列腺癌

评估患者个体活检可检出前列腺癌风险:需注意病例组合异质性与先验概率

Assessing a patient's individual risk of biopsy-detectable prostate cancer: Be aware of case mix heterogeneity and a priori likelihood.
PubMed 文献 · Eur Urol Oncol · 2019-08-18

前列腺特异性抗原(PSA)等活检前信息常整合于风险计算器(RC)。ERSPC-MRI RC 基于 961 名男性(2012-2017 年)临床队列开发,临床显著前列腺癌(csPC;Gleason ≥ 3+4)患病率 36%,区分度良好(受试者工作特征曲线下面积 0.84)。若使用场景与开发场景不同,绝对风险估计可能不准;对计算器截距做小幅更新可恢复准确性,支持基于本地有效风险估计的决策。

要点

  • ERSPC-MRI 风险计算器预测靶向和系统活检的临床显著前列腺癌(Gleason ≥ 3+4)。
  • 该计算器在 961 名男性队列中开发,csPC 患病率 36%,AUC 0.84。
  • 使用场景与开发场景不同时,需注意病例组合异质性,可小幅更新截距恢复准确性。

核心结论

  • 若风险计算器的使用场景与开发场景不同,基于错误绝对风险估计做临床决策存在风险;对计算器截距做小幅更新可恢复准确性,支持基于本地有效风险估计的决策。

研究设计与样本

  • ERSPC-MRI 风险计算器在 961 名男性(2012-2017 年)临床队列中开发,csPC 患病率 36%。
  • 该计算器利用 PSA、直肠指检、前列腺体积、年龄、既往阴性活检和前列腺影像报告和数据系统评分预测靶向和系统活检的 csPC(Gleason ≥ 3+4)。

主要发现

  • 该计算器区分度良好,受试者工作特征曲线下面积为 0.84。
  • 随着多参数磁共振成像使用增加,作者预见该计算器也将用于先验概率较低的前列腺癌男性,并研究了该情景对个体风险预测的影响。

关键数值与推荐

  • csPC 定义为 Gleason ≥ 3+4。
  • ERSPC-MRI 风险计算器纳入 PSA、直肠指检、前列腺体积、年龄、既往阴性活检和前列腺影像报告和数据系统评分。

临床怎么用

  • 作者认为,对计算器截距做小幅更新可恢复准确性,支持基于本地有效风险估计的决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The relation between prostate-specific antigen (PSA) and other relevant prebiopsy information is often combined in a risk calculator (RC). If the setting for RC use differs from that in which it was developed, there is a risk of making clinical decisions based on incorrect estimates of the absolute risk. The ERSPC-MRI RC predicts clinically significant prostate cancer (csPC; Gleason ≥ 3 + 4) on targeted and systematic biopsy using information on PSA, digital rectal examination, prostate volume, age, previous negative biopsy, and Prostate Imaging-Recording and Data System score. This calculator was developed on a clinical cohort of 961 men (2012-2017) with a csPC prevalence of 36%. Discrimination was good (area under the receiver operating characteristic curve 0.84). With the increasing use of multiparametric magnetic resonance imaging, we foresee that this RC will also be used for men with a lower a priori likelihood of PC. We investigated the effect of such a scenario on individual risk predictions. A small update of the intercept for the calculator can restore the accuracy to support decision-making with locally valid risk estimates. PATIENT SUMMARY: Decisions on who to refer for a prostate biopsy with its risk of sepsis and overdiagnosis require more than a prostate-specific antigen test. A prediction tool may take other relevant prebiopsy information into account, but may need to be updated to contemporary center-specific settings to provide accurate estimates of the risk of having prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Verbeek JFM, Nieboer D, Steyerberg EW, et al. Assessing a patient's individual risk of biopsy-detectable prostate cancer: Be aware of case mix heterogeneity and a priori likelihood. Eur Urol Oncol. 2019. PMID: 31431394. doi:10.1016/j.euo.2019.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。